secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pasithea Therapeutics Corp. (KTTA)
CIK:        0001841330
Form:       8-K
Filed at:   2023-07-20T23:59:59+00:00
Accession:  0001213900-23-058326
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Pasithea Therapeutics receives Nasdaq extension to Jan 15, 2024 for bid price compliance
--------------------------------------------------------------------------------

- Nasdaq granted 180-day extension to January 15, 2024 to regain $1.00 minimum bid price compliance.
- Previous non-compliance notice received Jan 19, 2023; extension granted Jul 19, 2023 to Jan 15, 2024.
- Company may consider reverse stock split; no assurance of regaining compliance.
- Failure to comply by deadline may result in Nasdaq delisting notice; Company can appeal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841330/000121390023058326/0001213900-23-058326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841330/000121390023058326/ea182058-8k_pasithea.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-058326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer